Septodont Holding Overview
Listing status vs. input list: The input list classifies the company as a "Public company". This is incorrect. Septodont Holding is unlisted and privately held. Its capital is wholly owned by the Schiller family: the former CEO and current Chairman Olivier Schiller, his father Henri Schiller, and his five children.
Septodont is the world's largest maker of dental local anesthetics and a family-controlled specialist in pharmaceutical dentistry. Its core franchise is injectable anesthetic cartridges. The group produces about 500 million per year, which management characterizes as roughly 20 cartridges injected every second worldwide, and historically more than half of global production. Around that core, Septodont has built adjacent businesses: needles and injection devices, topical anesthetics, reversal agents, bioactive restorative and endodontic materials based on its proprietary Active BioSilicate Technology (Biodentine, BioRoot RCS, BioRoot Flow), and surgical biomaterials. A third leg is sterile-injectable contract manufacturing (CDMO) through Novocol Pharma in Canada, which counts Moderna as an anchor client. The group has grown from EUR 199M (2014) to EUR 443M (2024), an 8.3% CAGR, financed with bank debt rather than outside equity. The 2024 Inibsa acquisition lifts it toward ~EUR 560M. Management's stated ambition is EUR 1bn of revenue by the 2032 centenary.
What the company does
Septodont develops, manufactures and distributes dental pharmaceuticals and medical devices. The Chairman's January 2025 description of the group's production scope covers:
-
injectable anesthetics;
-
topical anesthetics (applied locally without injection);
-
needles;
-
anesthetic reversal agents ("neutraliseurs d'anesthésique");
-
safety injection devices and syringes.
Beyond pain control, the company is active in:
endodontics: root canal sealers and obturation materials, with files now added through a partnership;
restorative dentistry: dentine substitutes;
surgical dentistry: hemostatics, alveolar dressings and synthetic membranes;
infection control: and related consumables.
Company's own description
Company boilerplate (Indeed / corporate profile) describes Septodont as enhancing lives through innovative, safe and effective healthcare solutions. It positions the company at the forefront of pharmaceutical dentistry since the Schiller family founded it in 1932, as still family-owned, and as the world leader in dental pain management. No statutory annual report is published, so no annual-report description is available.
Business model and revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Dental pain management (anesthetic cartridges, topicals, needles, syringes, reversal agents) | Product sales of consumables, recurring and volume-driven | Share of revenue not publicly disclosed. The Chairman notes pain control is only ~5% of a dentist's consumables spend, which bounds the addressable market |
| Dental biomaterials, restorative, endodontic and surgical products | Product sales of consumables | — |
| CDMO (Novocol Pharma, Canada): aseptic fill-finish, labelling and packaging for third parties | Contract manufacturing services, long-term supply agreements | — |
| Licensing / subscription | No material licensing or subscription revenue identified | — |
The model is overwhelmingly a product model: high-volume regulated consumables sold mainly through dental distributors and dealers, plus subsidiaries in key markets. A smaller but strategic service model comes from CDMO. Distribution is via subsidiaries or distributor networks in about 110 countries (Chairman, 2025). Older corporate boilerplate cites 150+ countries; the difference likely reflects a change in definition, from countries supplied to countries with active presence. Septodont sells worldwide except North Korea, Venezuela and Iran (Chairman, 2025).
Value-chain position
Septodont is vertically integrated:
R&D and regulatory: R&D centres in France and Canada, and product registrations in many jurisdictions (e.g., a first-in-40-years anesthetic registration in Japan).
Active-ingredient formulation and sterile manufacturing: automated washing, filling and terminal sterilization of cartridges.
Component manufacturing: needles and injection devices at Mazamet/Aussillon, France.
Commercialization: country subsidiaries and dealers.
It outsources selectively. For example, Ultracain cartridges acquired from Sanofi continue to be manufactured by Sanofi in Frankfurt under contract (ZWP Online, March 2022).
Customer types and end-markets
-
General dental practitioners and specialists (endodontists, oral surgeons, pediatric dentists), reached mainly through dental distributors and DSOs. The group has a "Global VP, Corporate Accounts" role, implying a key-account and DSO channel.
-
Hospitals and dental schools.
-
Pharmaceutical and biotech companies, as CDMO clients (Moderna).
-
Government health systems and tenders (implied by registrations in many national markets).
Independent characterization
Septodont is a classic French "ETI" (mid-sized company) "hidden champion": a dominant share in a narrow, highly regulated, low-ticket but indispensable consumable, protected by regulatory barriers and sterile-manufacturing know-how. Its strategic challenge, stated openly by the Chairman, is growth beyond a niche it already leads. Management is addressing this along three lines:
-
adjacency expansion within dentistry (biomaterials, endodontics);
-
sterile-injectable CDMO;
-
consolidation by acquisition (Sanofi dental brands, Inibsa).
The model is cash-generative, and the group has used leverage (capped at 3.5x EBITDA) rather than equity. That preserves family control but concentrates financial risk.
Strategy
Stated strategy (Chairman, Jan 2025)
Three growth avenues:
-
Consolidate global leadership in dental pain management.
-
Become a global dental player beyond anesthetics. Pain control is only ~5% of a dentist's EUR 100 consumables spend.
-
Leverage sterile-injectable know-how in non-dental CDMO.
Strategic matrix (markets x products):
Long-term target: EUR 1bn revenue by 2032, the company's centenary.
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Inibsa acquisition | Oct 2024 | +~EUR 80M revenue, production capacity, footprint in 60+ countries |
| Balanced Pharma investment | Dec 2024 / Jan 2025 | Next-gen anesthetics in standard cartridges |
| CEO succession | Mar–Jun 2025 | Khadr CEO; Schiller Chairman |
| Cost programme | 2,025 | Production costs -2% vs 2024; cost-focused finance executive hired |
| Saint-Maur modernization | Announced 2025 | ~EUR 30M to sustain French output |
| Endodontic complete solution | 2,025 | BioRoot Flow combined with GenENDO files via partnership |
| AI deployment | Ongoing | Sales prospect targeting, manufacturing root-cause analysis, pharmacovigilance reporting |
| CSR roadmap (four pillars) | Ongoing | Environment, communities, human capital, values |
Medium-term financial targets
-
FY2025 revenue ~EUR 560M.
-
EUR 1bn by 2032.
-
Leverage ≤3.5x EBITDA on acquisitions.
-
R&D 5–6% of revenue.
-
No margin targets publicly disclosed.
Products & Services
Pricing is not publicly disclosed for any product; products are sold through dealers at list prices that vary by country. Launch years are given only where verified.
Dental Pain Management
| Product / brand | Description & capabilities | Target customer | Launch / notes |
|---|---|---|---|
| Septanest / Septocaine (articaine HCl 4% with epinephrine) | Flagship injectable local anesthetic in cartridges. Articaine is used in >95% of local anesthesias in Germany (ZWP interview) | GPs, all dental specialties | US approval (as Septocaine) obtained |
| Ultracain (articaine) | Ex-Sanofi articaine brand, manufactured by Sanofi Frankfurt under contract | GPs (strong in Germany/Europe) | Acquired 2021–2022 |
| Scandonest (mepivacaine) | Vasoconstrictor-free and adrenaline variants | GPs, pediatric, cardiac-risk patients | Long-established |
| Cook-Waite brand anesthetics | US legacy anesthetic brand (lidocaine and others) | US dentists | Acquired 2017 |
| Lidostesim (lidocaine), Mepivalem (mepivacaine), Citanest (prilocaine) | Brazilian anesthetic brands produced at DLA Catanduva | Brazil / LatAm | Acquired 2016 |
| Inibsa anesthetic range | Spanish-made dental anesthetics; Inibsa had presence in 60+ countries | Iberia, LatAm, export | Acquired Oct 2024 |
| Topical anesthetic gels (incl. lidocaine gel) | Pre-injection gingival anesthesia | GPs | The Chairman cited a profitable lidocaine gel and a failed adjacent non-dental gel venture |
| OraVerse (phentolamine mesylate) | Reversal of soft-tissue anesthesia | GPs, pediatric | Acquired from Novalar, Mar 2011 |
| New buffered / pH-neutralized anesthetic technology | Removes acidity before injection for faster onset and less sting | US dentists | In development / roll-out (Chairman 2025); launch date n/d |
| Japan-registered anesthetic | First new dental anesthetic registered in Japan in ~40 years | Japan | Registered; year-1 sales limited by mandatory 1-year patient follow-up |
| Septoject needles | Dental needles; ~200M needles/year from a dedicated plant | All dentists | Mazamet plant |
| Ultra Safety Plus / Ultra Safety Plus Twist XL | Safety syringe system to reduce needlestick injuries | Hospitals, schools, clinics | Current |
| Dentapen | Electronic (battery-powered) injection syringe for controlled-flow injection | GPs, pediatric | Launched 2020 |
| Paroject | Intraligamentary / pressure syringe | GPs | Current |
| Dontisolon | Ex-Sanofi dental corticosteroid preparation | GPs | Acquired 2021–2022 |
Biomaterials, Restorative, Endodontic & Surgical
| Product / brand | Description | Target | Notes |
|---|---|---|---|
| Biodentine | Tricalcium-silicate bioactive dentine substitute (Active BioSilicate Technology, ABS). Allows vital teeth to be preserved in deep caries instead of devitalization | Restorative, endodontic, pediatric | >500 PubMed publications by 2019 |
| BioRoot RCS | ABS bioceramic root canal sealer | Endodontists, GPs | Current |
| BioRoot Flow | Bioceramic root canal sealer in flowable format; designed to make obturation effective even for non-specialists | GPs, endodontists | Recent launch (announced ~2024) |
| GenENDO | Endodontic file system, offered with BioRoot Flow as a complete obturation solution via a partnership with an instrument maker | GPs, endodontists | German launch Sept 2025 |
| Endomethasone N | Root canal paste | GPs | 1950s heritage product |
| Alveogyl | Alveolar osteitis (dry socket) dressing | Oral surgery / GPs | 1950s heritage product |
| Racestyptine | Hemostatic / retraction solution | Restorative, prosthodontics | 1950s heritage product |
| Hemogelatin | Hemostatic gelatin sponge for bleeding management | Oral surgery | Current |
| Synthetic surgical membranes (Biomedical Tissues) | Fully synthetic post-extraction membrane, an alternative to bovine collagen | Oral surgeons, implantologists | Acquired 2022 |
| TDV restorative accessories | Restorative auxiliaries manufactured in Pomerode | Brazil / LatAm | Acquired 2014 |
| Taloja (India) materials | Materials and other solutions | Export, India | India revenue < EUR 5M |
Digital and services
| Offering | Description |
|---|---|
| Septodont Companion app | Scan a product box to get country-specific product information and contact Septodont |
| CDMO services (Novocol Pharma) | Aseptic fill-finish into vials and syringes, labelling and packaging for sterile injectables and combination products; anchor client Moderna (mRNA respiratory vaccines) |
| Duoject device engineering | Injection-device design and engineering services |
Financial Narrative
Group-level income statement (consolidated)
Source: Chairman Olivier Schiller, École de Paris / La Fabrique transcript (session 21 Jan 2025). Currency: EUR. Septodont publishes no audited consolidated accounts.
Notes on the revenue figures:
-
FY2024 growth is +8.3% YoY (443/409).
-
The 10-year revenue CAGR for 2014–2024 is 8.3%, from EUR 199M in 2014. In the Q&A the Chairman also cited ~8.5% average growth.
-
FY2025 is guidance, not an actual: EUR 560M including ~EUR 80M from Inibsa, which implies organic plus other growth of ~EUR 37M (~8%).
-
CFNews (2024) cited Septodont revenue of ~EUR 410M at the time of the Inibsa deal, consistent with FY2023.
-
Revelio/Indeed estimates ("USD 100–500M") are superseded by the management figures.
Standalone accounts of SEPTODONT SAS (French operating company, SIREN 552 139 677)
Source: Pappers (RCS filings). EUR. The FY2025 revenue and net income are confirmed by Pappers' director page; the year labels for earlier columns are inferred from Pappers' standard newest-first ordering and should be checked against the filed accounts.
Latest export revenue for Septodont SAS is EUR 181M, roughly 78% of FY2025 standalone revenue. This shows the French entity functions largely as an export manufacturing and supply hub to group subsidiaries.
Interpretation: The French SAS's thin and volatile statutory margins are typical of a manufacturing and supply entity selling to affiliates under transfer pricing. They should not be read as group profitability. The FY2024 operating loss coincides with the Inibsa acquisition year and a cost-inflation issue flagged by the advisory board. In response, management hired a "cost killer" finance executive and set a 2025 target of a 2% cut in production costs (Chairman, Jan 2025). The FY2025 rebound to a EUR 7.58M operating profit is consistent with that programme.
Standalone accounts of SEPTODONT HOLDING SAS
Source: Pappers. Holding revenue reflects management fees and royalties; net income is likely dominated by subsidiary dividends.
Balance sheet, cash flow and ratios (group)
Disclosed financial policies (qualitative, Chairman 2025):
Leverage cap: net debt not to exceed 3.5x EBITDA on major acquisitions. Growth is financed with bank debt; private equity and Bpifrance-style equity are deliberately avoided to preserve control.
Capex commitment: ~EUR 30M to modernize the Saint-Maur-des-Fossés plant to keep French output stable. All future volume growth is to be located outside France.
Philanthropy: 0.5% of revenue (~EUR 2M/yr), the maximum tax-deductible rate.
R&D: 5–6% of revenue annually.
Ratios (ROE, ROA, ROIC, current ratio, D/E, net debt/EBITDA actuals, interest coverage, asset turnover, cash conversion cycle): not publicly disclosed. The only inference available is that post-Inibsa leverage is, by policy, at or below 3.5x EBITDA.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Contents | Key entities |
|---|---|---|
Dental: Pain Management | Injectable anesthetic cartridges (articaine, lidocaine, mepivacaine, prilocaine), topical anesthetics, needles, safety and electronic syringes, reversal agent | Septodont SAS (Saint-Maur), Mazamet/Aussillon plant, Novocol (Cambridge), DLA (Catanduva), Inibsa (Spain) |
Dental: Biomaterials, Restorative, Endodontic & Surgical | Biodentine, BioRoot RCS / BioRoot Flow, endodontic pastes, hemostatics, alveolar dressings, synthetic membranes, restorative accessories | Septodont SAS, TDV (Pomerode), Taloja (India), Biomedical Tissues |
CDMO (non-dental) | Aseptic fill-finish, labelling and packaging of sterile injectables (vials and syringes), incl. mRNA vaccines | Novocol Pharma (Cambridge, ON) |
Revenue by Segment
| Metric | FY2023 | FY2024 |
|---|---|---|
Group revenue (EUR Mn) | 409 | 443 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Country | Role | Disclosed data |
|---|---|---|---|
Septodont Holding SAS (428 207 922) | France | Family holding / top company | Standalone FY2022: revenue EUR 30M, net income EUR 25.1M, cash EUR 9.4M (Pappers) |
Septodont SAS (552 139 677) | France | Main French operating company, Saint-Maur | Standalone FY2025 revenue EUR 232M (see §6) |
Société Française d'Instruments de Chirurgie (Aussillon) | France | Needles and injection devices plant (Mazamet area) | FY2025 revenue EUR 12.7M, net income EUR 1.55M (Pappers) |
Biomedical Tissues SAS (525 280 038) | France | Synthetic membranes | FY2022 revenue EUR 0.124M, net loss EUR 0.198M; 3–5 employees (2023) |
Novocol Pharmaceutical of Canada Inc. (Novocol Pharma) | Canada | Anesthetic manufacturing and CDMO |
|
Duoject Medical Systems | Canada | Injection device design | — |
Septodont Inc. / Septodont North America | USA | Commercial | — |
TDV / DLA Pharma | Brazil | Manufacturing and commercial | — |
Septodont India (Taloja) | India | Materials manufacturing | India revenue < EUR 5M (Chairman 2025) |
Laboratorios Inibsa (controlling stake) | Spain | Anesthetics and dental products; ~EUR 80M revenue contribution | Acteon holds a minority stake |
Septodont GmbH | Germany | Commercial (DACH), Niederkassel | — |
Medtech (minority) | China | Distributor | — |
Income Statement
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Group revenue (EUR Mn) | 409 | 443 | — |
Group revenue guidance (EUR Mn) | — | — | 560 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Revenue (EUR Mn) | 180 | 203 | 205 | 232 |
Operating result (EUR Mn) | 8.23 | 5.84 | -3.15 | 7.58 |
Net income (EUR Mn) | 4.57 | 1.65 | -1.35 | 2.09 |
Operating margin (%) | 4.6 | 2.9 | -1.5 | 3.3 |
Net margin (%) | 2.5 | 0.8 | -0.7 | 0.9 |
Cash (EUR Mn) | — | — | — | 3.03 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement (FY2022)
| Metric | FY2022 |
|---|---|
Revenue (EUR Mn) | 30 |
Net income (EUR Mn) | 25.1 |
Cash (EUR Mn) | 9.4 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 |
|---|---|---|
R&D spend (% of revenue, stated range midpoint) | 5.5 | 5.5 |
Geographic Revenue
| Region | FY2023 share of revenue (%) | FY2023 revenue (EUR Mn, derived from 409 x share) |
|---|---|---|
Americas (mainly US and Canada) | 50 | 204.5 |
Europe, Middle East & Africa | 40 | 163.6 |
Asia-Pacific | 10 | 40.9 |
Region Overview
| Region | FY2023 |
|---|---|
Americas share (%) | 50 |
EMEA share (%) | 40 |
APAC share (%) | 10 |
Country Overview
| Country | Disclosure |
|---|---|
India | Revenue < EUR 5M; pricing strategy to be reset (lower prices and margin to gain volume) |
Brazil | Local manufacturing required to be competitive because of high import tariffs (TDV, DLA) |
Japan | New anesthetic registration; slow initial uptake |
Germany | Articaine >95% of local anesthesia; Ultracain and Septanest franchises |
Spain / Iberia | Strengthened by Inibsa (from Oct 2024) |
US | Largest single market (implied). Only ~50 sales reps, supported by an AI-based prospect-targeting tool that raised visit success from 2% to 20% |
Analyst Conclusions
Management guidance: ~EUR 560M FY2025 revenue (including Inibsa); EUR 1bn by 2032; 2% production-cost reduction in 2025; ~EUR 30M Saint-Maur capex.
Consensus: none (no analyst coverage).
Implied growth: reaching EUR 1bn by 2032 from EUR 560M in 2025 requires a ~8.6% CAGR. That is in line with the past decade's 8.3%, but likely needs further acquisitions.
Bull case
-
Inibsa integration plus cost discipline lifts scale and margins. The FY2025 standalone rebound at Septodont SAS (EUR 7.58M operating profit vs a EUR 3.15M loss) suggests the cost programme is working.
-
CDMO becomes a meaningful second growth engine on the back of the Moderna line, with injectables outgrowing other dosage forms.
-
Pipeline (buffered anesthetic, Balanced Pharma) and ABS biomaterials expand the addressable market beyond the ~5% pain-control slice.
Bear case
-
Leverage up to 3.5x EBITDA combined with integration risk could strain cash if dental volumes or vaccine demand soften.
-
Emerging-market price competition (India) and tariffs erode the anesthetic franchise.
-
CEO transition and family succession, combined with Europe's cost and regulatory burden, may slow execution. Note that all incremental growth is to be located outside France.
Key catalysts and monitorables (next 12 months)
-
FY2025 actual consolidated revenue versus the EUR 560M guide.
-
Inibsa synergy delivery.
-
Novocol utilization and any new CDMO clients.
-
Balanced Pharma regulatory progress.
-
US launch of the buffered anesthetic.
-
Progress on the Saint-Maur modernization.
-
Further bolt-on M&A.
-
First CSRD report.
-
Any leadership changes under the new CEO.
Analyst verdict
Septodont is a high-quality, family-controlled niche champion whose core franchise, dental local anesthesia, is structurally defensive. Cartridges are low-cost, indispensable, consumed procedure by procedure and protected by regulatory approvals and sterile-manufacturing expertise that are hard to replicate. The group's track record is strong. It more than doubled revenue in a decade at an 8.3% CAGR without diluting family ownership, and it executed a series of acquisitions that each served a clear purpose: tariff-driven localization in Brazil, device engineering at Duoject, articaine consolidation through Sanofi's Ultracain, and scale and geography through Inibsa.
The investment case now hinges on three transitions happening at once. First, a leadership handover to Karim Khadr, the first CEO outside the founding family. Second, digesting Inibsa, the largest acquisition in the group's history, while holding leverage within its self-imposed 3.5x EBITDA ceiling. Third, proving that diversification into biomaterials, endodontic systems and CDMO can make Septodont less dependent on a market slice that represents only ~5% of dentist consumables spend.
The limited transparency is the main analytical constraint. There are no consolidated margins, cash flows or debt figures, and the French operating entity's thin statutory profits (EUR 2.09M net on EUR 232M revenue in FY2025) reflect intra-group transfer pricing rather than group economics. Even so, the qualitative signals are constructive: decisive cost action in 2025, a profit rebound at the French entity, a well-supported CDMO anchor in Moderna, and a credible innovation pipeline.
On balance, Septodont looks positioned to sustain high-single-digit growth. The EUR 1bn 2032 target is ambitious but consistent with history, provided M&A continues and leverage is managed prudently. The principal risks to monitor are integration execution, emerging-market price erosion, vaccine-volume volatility at Novocol and European cost competitiveness. Overall view: a resilient, well-governed private compounder with moderate execution risk over the next two to three years.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Karim Khadr | Chief Executive Officer; président of Biomedical Tissues (since 22 Sep 2025); officer of Septodont Holding and Septodont SAS (Pappers) | Joined 28 Jul 2021 as President, Dental Division; CEO since 2 Jun 2025 | Born July 1964 (Pappers). |
Olivier Schiller | Chairman (non-executive président) | CFO, then président 2012–Jun 2025; Chairman since Jun 2025 | Engineer, École Centrale de Lille; Arthur Andersen consultant; HEC MBA. Advisor to Banque de France; Conseiller du Commerce extérieur; NYU College of Dentistry strategic council; VP of METI; ETI Ambassador to French government 2020–2022. Turned 65 in 2025 |
Henri Schiller | Shareholder; formerly chairman of supervisory board | Led company from the 1960s | Father of Olivier Schiller |
Atif Zia | Chief Operating Officer, Septodont; President, Novocol Pharma; Board member, Balanced Pharma | — | Operations / CDMO leader |
David Benovy | Global VP, Corporate Accounts | — | Ex-Dentsply, Dental Services Group |
Jérôme Haas | Director of Corporate Marketing (as last reported) | — | — |
Axel Reimann | Managing Director, Septodont GmbH (as last reported) | — | — |
Major Shareholders
| Holder | Stake |
|---|---|
Schiller family (Henri Schiller, Olivier Schiller, his five children) | 100% of Septodont (per Chairman, Jan 2025) |
Institutional holders | None (unlisted) |
Inibsa minority | Acteon holds a non-controlling stake in Inibsa (subsidiary level only) |
Competitive Landscape
Competitors by Segment
| Business line | Competitors |
|---|---|
Dental anesthetics | Dentsply Sirona; Pierrel S.p.A. (Italy, listed on Euronext Milan, articaine CMO/brand); Inibsa (now controlled by Septodont); Novocol legacy rivals; Hospira/Pfizer (historical); regional generics makers (India, China, Brazil) |
Endodontics / biomaterials | Dentsply Sirona; Envista (Kerr); Coltene; FKG Dentaire; Angelus (Brazil, MTA); Brasseler; Ultradent |
Restorative / bioactive | Solventum (ex-3M Oral Care); GC Corporation; Ivoclar; Kulzer; VOCO; Ultradent |
Surgical biomaterials | Geistlich; Straumann Group; Zimmer Biomet Dental (now ZimVie / Envista lines) |
Dental equipment / injection devices | Acteon (also Inibsa partner); Milestone Scientific (The Wand) |
CDMO sterile fill-finish | Vetter, Recipharm, Baxter BioPharma Solutions (Simtra), Catalent (Novo Holdings), Delpharm, PCI Pharma |
Peer Comparison FY2024
| Metric | Septodont | Dentsply Sirona | Envista | Acteon |
|---|---|---|---|---|
Ownership | Private, family | Listed (NASDAQ: XRAY) | Listed (NYSE: NVST) | Private |
Latest revenue | EUR 443M (FY2024) | ~USD 3.8bn (FY2024; verify in 10-K) | ~USD 2.5bn (FY2024; verify in 10-K) | ~EUR 200M (CFNews, 2024) |
Revenue growth | +8.3% (FY2024) | Negative (FY2024; verify) | Flat to slightly negative (FY2024; verify) | — |
Margins | — | Per 10-K | Per 10-K | — |
R&D intensity | 5–6% | Per 10-K | Per 10-K | — |
Recent Developments
Relevant items from late 2024 and early 2025 are included for context and marked "(context)".
Not identified in public sources for this period: * litigation, regulatory actions, layoffs, restructurings or guidance revisions.



